Rapid Automated Circulating Tumor DNA (ctDNA) Enrichment Directly from Plasma
INTRODUCTION:
Blood liquid biopsy contains circulating cell-free DNA (cfDNA), a portion of which may be shed from tumors. This circulating tumor-derived DNA (ctDNA) can be tested to identify cancerous mutations. DNAe is developing the first rapid, sample-to-result, NGS-based solution, the LiDia-SEQTM platform, enabling clinically relevant sequencing results to be reported within a single work shift for use in routine care. As part of its automated NGS workflow development, DNAe has developed a proprietary method to rapidly capture and enrich mutations of cancer ctDNA directly from plasma, named Specific Variant Capture (SVC).
